Study on Plasma NT-proBNP Levels and Coronary Artery Disease Severity in Patients Undergoing Elective Coronary Angiography

What this Trial Is About

Researchers are investigating the relationship between plasma NT-proBNP levels and the presence, extent, and severity of artery narrowing in patients suspected of having coronary artery disease CAD. This observational study focuses on patients referred for elective diagnostic coronary angiography based on symptoms or signs of CAD. The purpose is to better understand how NT-proBNP levels correlate with the burden of coronary artery disease in a real-world patient population. The study involves measuring plasma NT-proBNP levels in patients during hospitalization, specifically on the morning before their coronary angiography procedure. The extent and severity of coronary artery narrowing are independently assessed by two experienced cardiologists during and immediately after the angiography. Patients with conditions that may affect NT-proBNP levels, such as heart failure, severe valvular disease, atrial fibrillation, severe chronic kidney disease, prior coronary artery bypass surgery, or those over 80 years old are excluded to ensure accurate evaluation. Participants will undergo blood tests and coronary angiography as part of their regular hospital care. Researchers will analyze the NT-proBNP levels alongside angiographic findings to determine any associations. The primary outcome is the correlation between plasma NT-proBNP levels and the presence and severity of coronary artery lesions. The study began in September 2021 and is expected to conclude by July 2025, with no additional long-term follow-up reported.

Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease